Modern treatment approaches for erectile dysfunction – review

• Authors: Kamil Nikel , Michał Stojko , Joanna Smolarczyk , Magdalena Piegza

Title variants

PL

Nowoczesne podejścia terapeutyczne w leczeniu dysfunkcji erekcyjnej – przegląd

Abstracts

PL

Zaburzenia erekcji (erectile dysfunction – ED) są istotnym problemem zdrowia publicznego, wpływającym zarówno na jakość życia pacjentów, jak i ich relacje intymne. Chociaż inhibitory fosfodiesterazy typu 5 (phosphodiesterase type 5 inhibitors – PDE5-Is) stanowią standardowe leczenie pierwszego rzutu, znaczna część pacjentów nie osiąga zadowalających rezultatów. Rosnące zainteresowanie alternatywnymi metodami leczenia doprowadziło do eksploracji nowych terapii, w tym neurotoksyny botulinowej (botulinum neurotoxin – BoNT). BoNT zwiększa dopływ krwi do tkanek prącia poprzez rozluźnienie mięśni gładkich ciał jamistych dzięki hamowaniu uwalniania acetylocholiny.
W niniejszym przeglądzie omówiono BoNT jako nowy środek w leczeniu ED oraz porównano bezpieczeństwo jej stosowania i skuteczność z zaawansowanymi metodami, takimi jak terapia endowaskularna, terapia komórkami macierzystymi, terapia osoczem bogatopłytkowym oraz terapia falą uderzeniową o niskiej intensywności. Omówiono mechanizmy działania, wyniki badań klinicznych oraz możliwe ograniczenia tych metod. Według najnowszych badań BoNT jest obiecującą alternatywą dla pacjentów z ED, którzy nie reagują na tradycyjne leczenie. Konieczne są jednak dodatkowe badania w celu ustalenia optymalnych schematów dawkowania oraz określenia długoterminowych korzyści nowych podejść terapeutycznych.

EN

Erectile dysfunction (ED) is a significant public health issue that affects both patients’ quality of life and their intimate relationships. While phosphodiesterase type 5 inhibitors (PDE5-Is) are the standard first-line treatment, a substantial proportion of patients fail to achieve satisfactory results. Growing interest in alternative treatment approaches has led to the exploration of novel therapies, including botulinum neurotoxin (BoNT). BoNT increases penile tissue blood supply by relaxing corpora cavernosa smooth muscle by inhibiting the release of acetylcholine. In this review, BoNT as a new agent in the treatment of ED and comparison with the safety and efficacy of advanced techniques like endovascular therapy, stem cell therapy, platelet-rich plasma therapy, and low-intensity shockwave therapy is discussed. The mechanisms of action, clinical trial results, and possible limitations of these approaches are discussed. According to recent research, BoNT is a potential alternative for ED patients who are not responsive to traditional treatments. Additional studies, however, are required to establish optimal dosing regimens and determine the long-term benefits of these new therapeutic approaches.

Keywords

EN

erectile dysfunction; modern treatment; botulinum toxin; sexual health

PL

dysfunkcja erekcyjna; nowoczesne leczenie; toksyna botulinowa; zdrowie seksualne

• Publisher: Śląski Uniwersytet Medyczny w Katowicach
• Journal: Annales Academiae Medicae Silesiensis
• Year: 2025
• Volume: 79
• Pages: 159-167

Dates

published

2025

Contributors

author

Kamil Nikel

• Students’ Scientific Club, Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

• https://orcid.org/0009000798517129

author

Michał Stojko

• Students’ Scientific Club, Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

• https://orcid.org/0009000049603185

author

Joanna Smolarczyk

• Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

• https://orcid.org/0000000342978974

author

Magdalena Piegza

• Department of Psychiatry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

• https://orcid.org/0000000280097118

References

• Kitaw T.A., Abate B.B., Tilahun B.D., Yilak G., Rede M.B., Getie A. et al. The global burden of erectile dysfunction and its associated risk factors in diabetic patients: an umbrella review. BMC Public Health 2024; 24(1): 2816, doi: 10.1186/s12889-024-20300-7.
• Goldstein I., Goren A., Li V.W., Tang W.Y., Hassan T.A. Epidemiology update of erectile dysfunction in eight countries with high burden. Sex. Med. Rev. 2020; 8(1): 48–58, doi: 10.1016/j.sxmr.2019.06.008.
• Yuan P., Chen Y., Sun T., Cui L., Wei Y., Li T. et al. Exploring potential genes and mechanisms linking erectile dysfunction and depression. Front. Endocrinol. 2023; 14: 1221043, doi: 10.3389/fendo.2023.1221043.
• Terentes-Printzios D., Ioakeimidis N., Rokkas K., Vlachopoulos C. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nat. Rev. Cardiol. 2022; 19(1): 59–74, doi: 10.1038/s41569-021-00593-6.
• Takefuji Y. Exploring trends in erectile dysfunction research from 2017 to 2023: a focus on COVID-19, mental health, psychiatry, and drug. Sex. Disabil. 2024; 42: 521–526, doi: 10.1007/s11195-024-09841-2.
• Mirone V., Fusco F., Cirillo L., Napolitano L. Erectile dysfunction: from pathophysiology to clinical assessment. In: C. Bettocchi, G.M. Busetto, G. Carrieri, L. Cormio [eds]. Practical Clinical Andrology. Springer, Cham. 2023, p. 25–33, doi: 10.1007/978-3-031-11701-5_3.
• de Souza I.L.L., Ferreira E.D.S., Vasconcelos L.H.C., Cavalcante F.A., da Silva B.A. Erectile dysfunction: key role of cavernous smooth muscle cells. Front. Pharmacol. 2022; 13: 895044, doi: 10.3389/fphar.2022.895044.
• Caretta N., Feltrin G., Tarantini G., D’Agostino C., Tona F., Schipilliti M. et al. Erectile dysfunction, penile atherosclerosis, and coronary artery vasculopathy in heart transplant recipients. J. Sex. Med. 2013; 10(9): 2295–2302, doi: 10.1111/jsm.12233.
• Benevento B.T., Sipski M.L. Neurogenic bladder, neurogenic bowel, and sexual dysfunction in people with spinal cord injury. Phys. Ther. 2002; 82(6): 601–612, doi: 10.1093/ptj/82.6.601.
• Reddy A.G., Dick B.P., Natale C., Akula K.P., Yousif A., Hellstrom W.J.G. Application of botulinum neurotoxin in male sexual dysfunction: where are we now? Sex. Med. Rev. 2021; 9(2): 320–330, doi: 10.1016/j.sxmr.2020.05.004.
• Veiga L., Carolino E., Santos I., Veríssimo C., Almeida A., Grilo A. et al. Depressive symptomatology, temperament and oxytocin serum levels in a sample of healthy female university students. BMC Psychol. 2022; 10(1): 36, doi: 10.1186/s40359-022-00744-5.
• Zahr R.A., Kheir G.B., Mjaess G., Jabbour T., Chalhoub K., Diamand R. et al. Intra-cavernosal injection of botulinum toxin in the treatment of erectile dysfunction: a systematic review and meta-analysis. Urology 2022; 170: 5–13, doi: 10.1016/j.urology.2022.08.039.
• Mauermann M.L., Tracy J.A., Singer W. Autonomic neuropathies. In: E. Benarroch [ed.]. Autonomic neurology. Contemporary Neurology Series. New York, 2014; online edn, Oxford Academic, p. 205–216, doi: 10.1093/med/9780199920198.003.0015.
• Giuliano F., Denys P., Joussain C. Safety and effectiveness of repeated botulinum toxin A intracavernosal injections in men with erectile dysfunction unresponsive to approved pharmacological treatments: real-world observational data. Toxins 2023; 15(6): 382, doi: 10.3390/toxins15060382.
• Abdelrahman I.F.S., Raheem A.A., Elkhiat Y., Aburahma A.A., Abdel-Raheem T., Ghanem H. Safety and efficacy of botulinum neurotoxin in the treatment of erectile dysfunction refractory to phosphodiesterase inhibitors: results of a randomized controlled trial. Andrology 2022; 10(2): 254–261, doi: 10.1111/andr.13104.
• Giuliano F., Joussain C., Denys P. Safety and efficacy of intracavernosal injections of abobotulinumtoxinA (Dysport®) as add-on therapy to phosphodiesterase type 5 inhibitors or prostaglandin E1 for erectile dysfunction–case studies. Toxins 2019; 11(5): 283, doi: 10.3390/toxins11050283.
• El‐Shaer W., Ghanem H., Diab T., Abo-Taleb A., Kandeel W. Intra‐cavernous injection of BOTOX® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: randomized controlled trial. Andrology 2021; 9(4): 1166–1175, doi: 10.1111/andr.13010.
• Giuliano F., Denys P., Joussain C. Effectiveness and safety of intracavernosal incobotulinumtoxinA (Xeomin®) 100 U as an add-on therapy to standard pharmacological treatment for difficult-to-treat erectile dysfunction: a case series. Toxins 2022; 14(4): 286, doi: 10.3390/toxins14040286.
• Abdel Raheem A., Ghanem H., Fathy I., Ahmed A., Elkhiat Y., Abdel-Raheem Aly T.M. PS-05-007 Safety and efficacy of intra-cavernosal botulinum toxin injection in the treatment of patients with severe erectile dysfunction. J. Sex. Med. 2019; 16(5 Suppl 2): S15–S16, doi: 10.1016/j.jsxm.2019.03.076.
• Masterson T.A., Molina M., Ledesma B., Zucker I., Saltzman R., Ibrahim E. et al. Platelet-rich plasma for the treatment of erectile dysfunction: a prospective, randomized, double-blind, placebo-controlled clinical trial. J. Urol. 2023; 210(1): 154–161, doi: 10.1097/JU.0000000000003481.
• Poulios E., Mykoniatis I., Pyrgidis N., Zilotis F., Kapoteli P., Kotsiris D. et al. Plateletrich plasma (PRP) improves erectile function: a double-blind, randomized, placebo-controlled clinical trial. J. Sex. Med. 2021; 18(5): 926–935, doi: 10.1016/j.jsxm.2021.03.008.
• Shaher H., Fathi A., Elbashir S., Abdelbaki S.A., Soliman T. Is platelet rich plasma safe and effective in treatment of erectile dysfunction? Rando-mized controlled study. Urology 2023; 175: 114–119, doi: 10.1016/j.urology.2023.01.028.
• Saltzman R.G., Molina M.L., Ledesma B.R., Ibrahim E., Masterson T.A., Ramasamy R. Rationale and design for the COCKTAIL trial: a single-center, randomized, double-blind, sham-controlled study combining shockwave therapy and platelet-rich plasma for erectile dysfunction. Eur. Urol. Focus 2023; 9(1): 8–10, doi: 10.1016/j.euf.2022.09.015.
• Zaazaa A., Eid M.A., GamalEl Din S.F., Zeidan A., Hakeem A.A., Farag M.A.F. et al. Evaluation of plateletrich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study. Int. Urol. Nephrol. 2025; 57(1): 27–34, doi: 10.1007/s11255-024-04139-w.
• Leitão A.E., Vieira M.C.S., Pelegrini A., da Silva E.L., Guimarães A.C.A. A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas 2021; 145: 78–85, doi: 10.1016/j.maturitas.2020.12.002.
• Rislanu A., Auwal H., Musa D., Auwal A. Comparative effectiveness of electrical stimulation and aerobic exercise in the management of erectile dysfunction: a randomized clinical trial. Ethiop. J. Health Sci. 2020; 30(6): 961–970, doi: 10.4314/ejhs.v30i6.14.
• La Vignera S., Condorelli R., Vicari E., D’Agata R., Calogero A. Aerobic physical activity improves endothelial function in the middle-aged patients with erectile dysfunction. Aging Male 2011; 14(4): 265–272, doi: 10.3109/13685538.2010.544344.
• Al Demour S., Jafar H., Adwan S., AlSharif A., Alhawari H., Alrabadi A. et al. Safety and potential therapeutic effect of two intracavernous autolo-gous bone marrow-derived mesenchymal stem cells injections in diabetic patients with erectile dysfunction: an open-label phase I clinical trial. Urol. Int. 2018; 101(3): 358–365, doi: 10.1159/000492120.
• Levy J.A., Marchand M., Iorio L., Cassini W., Zahalsky M.P. Determi-ning the feasibility of managing erectile dysfunction in humans with placental-derived stem cells. J. Am. Osteopath. Assoc. 2016; 116(1): e1–e5, doi: 10.7556/jaoa.2016.007.
• You D., Jang M.J., Song G., Shin H.C., Suh N., Kim Y.M. et al. Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. Cytotherapy 2021; 23(10): 931–938, doi: 10.1016/j.jcyt.2021.06.001.
• Koga S., Horiguchi Y. Efficacy of a cultured conditioned medium of exfoliated deciduous dental pulp stem cells in erectile dysfunction patients. J. Cell. Mol. Med. 2022; 26(1): 195–201, doi: 10.1111/jcmm.17072.
• Kennady E.H., Bryk D.J., Ali M.M., Ratcliffe S.J., Mallawaarachchi I.V., Ostad B.J. et al. Low-intensity shockwave therapy improves baseline erectile function: a randomized sham-controlled crossover trial. Sex. Med. 2023; 11(5): qfad053, doi: 10.1093/sexmed/qfad053.
• De Oliveira P.S., De Oliveira T.R., Nunes Á., Martins F., Lopes T. Low-intensity shock wave therapy for erectile dysfunction and the influen-ce of disease duration. Arch. Ital. Urol. Androl. 2019; 90(4): 276–282, doi: 10.4081/aiua.2018.4.276.
• Kalyvianakis D., Mykoniatis I., Pyrgidis N., Kapoteli P., Zilotis F., Hatzichristou D. The effect of combination treatment with low-intensity shockwave therapy and daily tadalafil on severe erectile dysfunction: a double-blind, randomized, sham-controlled clinical trial. J. Sex. Med. 2024; 21(6): 533–538, doi: 10.1093/jsxmed/qdae038.
• Kalyvianakis D., Mykoniatis I., Memmos E., Kapoteli P., Memmos D., Hatzichristou D. Low-intensity shockwave therapy (LiST) for erectile dysfunction: a randomized clinical trial assessing the impact of energy flux density (EFD) and frequency of sessions. Int. J .Impot. Res. 2020; 32(3): 329––337, doi: 10.1038/s41443-019-0185-0.
• Olsen A.B., Persiani M., Boie S., Hanna M., Lund L. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand. J. Urol. 2015; 49(4): 329–333, doi: 10.3109/21681805.2014.984326.
• Aschenbach R., Steiner T., Kerl M.J., Zangos S., Basche S., Vogl T.J. Endovascular embolisation therapy in men with erectile impotence due to veno-occlusive dysfunction. Eur. J. Radiol. 2013; 82(3): 504–507, doi: 10.1016/j.ejrad.2012.10.030.

Identifiers

DOI

10.18794/aams/205195

Biblioteka Nauki

61259635